Login to Your Account

Aegera Raises C$17M In First Round To Fund Two Platforms

By Karen Young

Tuesday, March 5, 2002
Aegera Therapeutics Inc. raised C$17 million (US$10.7 million) in a private round of financing, which it will use to move its XIAP antisense program into Phase I trials in cancer next year. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription